T
Timothy Vollmer
Researcher at University of Colorado Boulder
Publications - 239
Citations - 19735
Timothy Vollmer is an academic researcher from University of Colorado Boulder. The author has contributed to research in topics: Multiple sclerosis & Glatiramer acetate. The author has an hindex of 65, co-authored 225 publications receiving 18204 citations. Previous affiliations of Timothy Vollmer include Anschutz Medical Campus & Montreal Neurological Institute and Hospital.
Papers
More filters
Journal ArticleDOI
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Stephen L. Hauser,Emmanuelle Waubant,Douglas L. Arnold,Timothy Vollmer,Jack P. Antel,Robert J. Fox,Amit Bar-Or,Michael Panzara,Neena Sarkar,Sunil Agarwal,Annette Langer-Gould,Craig H. Smith +11 more
TL;DR: A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks and provides evidence of B-cell involvement in the pathophysiology of relapsing-remitting multiple sclerosis.
Journal ArticleDOI
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis Results of a phase III multicenter, double‐blind, placebo‐controlled trial
Kenneth P. Johnson,Benjamin Rix Brooks,Jeffrey A. Cohen,Corey C. Ford,Jonathan Goldstein,Robert P. Lisak,Lawrence W. Myers,H. S. Panitch,John W. Rose,R. B. Schiffer,Timothy Vollmer,L. P. Weiner,Jerry S. Wolinsky +12 more
TL;DR: It is demonstrated that copolymer 1 treatment can significantly and beneficially alter the course of relapsing-remitting multiple sclerosis in a well-tolerated fashion.
Journal ArticleDOI
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial†
Kathleen Hawker,Paul O'Connor,Mark S. Freedman,Peter A. Calabresi,Jack P. Antel,Jack H. Simon,Stephen L. Hauser,Emmanuelle Waubant,Timothy Vollmer,Hillel Panitch,Jiameng Zhang,Peter Chin,Craig H. Smith +12 more
TL;DR: Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS).
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis : results of a phase III multicenter, double-blind, placebo-controlled trial
Kenneth P. Johnson,Benjamin Rix Brooks,Jeffrey A. Cohen,Corey C. Ford,Jonathan Goldstein,Robert P. Lisak,Lawrence W. Myers,H. S. Panitch,John W. Rose,R. B. Schiffer,Timothy Vollmer,L. P. Weiner,Jerry S. Wolinsky +12 more
TL;DR: Copolymer 1 (Copaxone) was studied in a multicenter (11-university) phase III trial of patients with relapsing-remitting multiple sclerosis and significantly more patients receiving copolym 1 were found to have improved and more receiving placebo worsened.
Journal ArticleDOI
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Peter A. Calabresi,Ernst Wilhelm Radue,Douglas S. Goodin,Douglas Jeffery,Kottil Rammohan,Anthony T. Reder,Timothy Vollmer,Mark A. Agius,Mark A. Agius,Ludwig Kappos,Tracy Stites,Bingbing Li,Linda Cappiello,Philipp von Rosenstiel,Fred D. Lublin +14 more
TL;DR: The findings substantiate the beneficial profile of fingolimod as a disease-modifying agent in the management of patients with relapsing-remitting multiple sclerosis and strengthen evidence for its beneficial effects on relapse rates in patients with relapse rates.